Differential protein expression in the epidermis of wild-type and COX-2 transgenic mice

Skin Pharmacology and Physiology

Volumn 19, Issue 2, 2006, Pages 89-94

  Muller Decker K ^a   Furstenberger G ^a   Neumann, M ^a   Schnolzer M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cyclooxygenase; Hair follicle biology; Prostaglandins; Squamous cell carcinoma; Transgenic epidermis

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; KERATIN; KERATIN 5; PROSTAGLANDIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DYSPLASIA; ENZYME ACTIVATION; EPIDERMIS; GENE OVEREXPRESSION; HAIR FOLLICLE; HYPERPLASIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; STRESS; TISSUE INJURY; TISSUE REGENERATION; TRANSGENIC MOUSE;

ANIMALS; CYCLOOXYGENASE 2; EPIDERMIS; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; REGENERATION; SKIN; SKIN NEOPLASMS;

EID: 33646587317     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091975     Document Type: Conference Paper

References (32)

1. Smith WL, Dewitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
2. Müller-Decker K, Leder C, Neumann M, Neufang G, Bayerl C, Schweizer J, Marks F, Fürstenberger G: Expression of cyclooxygenase isozymes during hair morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression. J Invest Dermatol 2003;121:661-668.
3. Neufang G, Fürstenberger G, Heidt M, Marks F, Müller-Decker K: Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 2001;98:7629-7634.
4. Scholz K, Fürstenberger G, Müller-Decker K, Marks F: Differential expression of prostaglandin H-synthase isoenzymes in normal and activated keratinocytes in vivo and in vitro. Biochem J 1995;306:263-269.
5. Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Fürstenberger G: Localization of prostaglandin H synthase isozymes in murine epidermal tumors: suppression of skin tumor promotion by inibition of prostaglandin H synthase 2. Mol Carcinog 1998;23:36-44.
6. Müller-Decker K, Hirschner W, Marks F, Fürstenberger G: The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol 2002;119:1189-1195.
7. Kämpfer H, Bräutigam L, Geisslinger G, Pfeilschifter J, Frank S: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol 2003;120:880-890.
8. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M: Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003;192:294-306.
9. Müller-Decker K, Reinerth G, Krieg P, Zimmermann R, Heise H, Bayerl C, Marks F, Fürstenberger G: Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999;82:648-656.
10. Müller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Fürstenberger G: Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002;99:12483-12488.
11. Marks F, Furstenberger G: Cancer prevention through interruption of multistage carcinogenesis: the lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur J Cancer 2000;36:314-329.
12. Gupta RA, DuBois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
13. Dannenberg AJ, Lippmann SM, Mann JR, Subbaramaiah K, DuBois RN: Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-266.
14. Rivers JK, Ariette J, Shear N, Guenther L, Carey W, Poulin Y: Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146:1-7.
15. Pentland AJ: Cyclooxygenase inhibitors for skin cancer prevention. Are they beneficial enough? Arch Dermatol 2002;138:751-755.
16. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al: The effect of celecoxib a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
17. Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-615.
18. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trazaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in APC716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803-809.
19. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-4708.
20. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
21. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-3401.
22. Wiese FW, Thompson PA, Kadlubar FF: Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001;21:5-10.
23. Fuchs E: Keratins and the skin. Annu Rev Cell Dev Biol 1995;11:123-153.
24. Müller-Decker K, Scholz K, Neufang G, Marks F, Fürstenberger G: Localization of prostaglandin-h synthase-1 and -2 in mouse skin: implications for cutaneous function. Exp Cell Res 1998;242:84-91.
25. Müller-Decker K, Scholz K, Marks F, Fürstenberger G: Differential expression of prostaglandin h synthase isozymes during multistage carcinogenesis in mouse epidermis. Molec Carcinog 1995;12:31-41.
26. Müller-Decker K, Berger I, Ackermann K, Ehemann V, Zoubova S, Aulmann S, Pyerin W, Fürstenberger G: Cystic duct dilatations and epithelial proliferations in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol 2005;166:575-584.
27. Klein RD, Abbey NW, Sabichi AL, de la Cerda J, Van Pelt CS, Fischer SM, Fürstenberger G, Müller-Decker K: Transitional cell hyperplasia and carcinomas in the bladders of transgenic mice with keratin 5 promoter-driven COX-2 overexpression. Cancer Res 2005;65:1808-1813.
28. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nature Rev Cancer 2003;3:267-275.
29. Bredemeyer AJ, Lewis RM, Malone JP, Davis AE, Gross RJ, Townsend R, Ley TJ: A proteomic approach for the discovery of protease substrates. Proc Natl Acad Sci USA 2004;101:11785-11790.
30. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnölzer M, Sinha P, Federici G: A proteomic investigation into etoposide chemoresistance of neuroblastoma cell lines. Proteomics 2005;5:796-804.
31. Poland J, Urbani A, Lage H, Schnölzer M, Sinha P: Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis 2004;25:173-183.
32. Schutt F, Ueberle B, Schnölzer M, Holz F, Kopitz J: Proteome analysis of lipofuscin in human retinal pigment epithelial cells. FEBS Lett 2002;25:528:217-221.